Table V.
Univariable and multivariable Cox regression analysis of the overall survival rate of the ccRCC patients.
| Parameters | Univariable analysis
|
Multivariable analysis
|
||||
|---|---|---|---|---|---|---|
| χ2 | P-value | HR (95 CI) | χ2 | P-value | HR (95 CI) | |
| Sex | ||||||
| Female vs. Male | 0.48 | 0.486 | 0.52 (0.08-3.21) | |||
| Age (years) | ||||||
| >62 vs. ≤62 | 1.99 | 0.157 | 0.32 (0.06-1.54) | |||
| Tumor size (cm) | ||||||
| >7 vs. ≤7 | 1.08 | 0.297 | 2.62 (0.42-16.06) | |||
| Tumor stage | ||||||
| T3+4 vs. T1+2 | 0.04 | 0.824 | 1.30 (2.64-585.07) | |||
| Histological ISUP grade | ||||||
| 3+4 vs. 1+2 | 7.11 | 0.007 | 39.37 (0.12-13.51) | 10.94 | <0.001 | 12.55 (2.80-56.18) |
| SHH mRNA levels | ||||||
| ↑ vs. ↓ | 2.84 | 0.091 | 23.76 (0.59-945.48) | |||
| SMO mRNA levels | ||||||
| ↑ vs. ↓ | 2.58 | 0.107 | 0.07 (0.01-1.76) | |||
| SUFU mRNA levels | ||||||
| ↑ vs. ↓ | 0.10 | 0.747 | 2.04 (0.026-159.89) | |||
| GLI2 mRNA levels | ||||||
| ↑ vs. ↓ | 0.15 | 0.698 | 0.47 (0.01-20.22) | |||
| GLI3 mRNA levels | ||||||
| ↑ vs. ↓ | 0.17 | 0.675 | 0.49 (0.02-13.27) | |||
| GLI1 mRNA levels | ||||||
| ↑ vs. ↓ | 1.24 | 0.265 | 8.10 (0.20-321.45) | |||
| PTCH1 mRNA levels | ||||||
| ↑ vs. ↓ | 3.72 | 0.053 | 0.18 (0.03-1.02) | |||
| BCL2 mRNA levels | ||||||
| ↑ vs. ↓ | 0.64 | 0.420 | 0.44 (0.06-3.16) | |||
| CCND1 mRNA levels | ||||||
| ↓ vs. ↑ | 3.93 | 0.047 | 12.63 (1.03-154.95) | 0.07 | 0.781 | 1.14 (0.43-3.01) |
| MYC mRNA levels | ||||||
| ↑ vs. ↓ | 0.01 | 0.901 | 1.29 (0.02-78.98) | |||
| VEGFA mRNA levels | ||||||
| ↑ vs. ↓ | 4.12 | 0.042 | 10.09 (1.08-93.97) | 4.17 | 0.041 | 3.72 (1.05-13.17) |
HR, hazard ratio; CI, confidence interval; ccRCC, clear cell renal cell carcinoma; SHH, sonic hedgehog; SMO, smoothened; SUFU, suppressor of fused homolog; GLI1, 2, 3, glioma-associated zinc finger protein 1, 2, 3; PTCH1, patched 1; BCL2, BCL2 apoptosis regulator; CCND1, cyclin D1; MYC, MYC proto-oncogene; VEGFA, vascular endothelial growth factor A.